WallStSmart

BlackRock Inc (BLK)vsApplied DNA Sciences, Inc. (BNBX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BlackRock Inc generates 1304013% more annual revenue ($27.30B vs $2.09M). BLK leads profitability with a 24.1% profit margin vs 0.0%. BLK appears more attractively valued with a PEG of 1.12. BLK earns a higher WallStSmart Score of 76/100 (B+).

BLK

Strong Buy

76

out of 100

Grade: B+

Growth: 8.7Profit: 7.5Value: 5.7Quality: 4.0
Piotroski: 1/9Altman Z: 1.14

BNBX

Hold

48

out of 100

Grade: D+

Growth: 5.3Profit: 2.5Value: 5.3Quality: 4.3
Piotroski: 3/9Altman Z: -130.37

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLK5 strengths · Avg: 9.2/10
Operating MarginProfitability
35.1%10/10

Strong operational efficiency at 35.1%

Revenue GrowthGrowth
30.6%10/10

Revenue surging 30.6% year-over-year

Market CapQuality
$171.40B9/10

Large-cap with strong market position

Profit MarginProfitability
24.1%9/10

Keeps 24 of every $100 in revenue as profit

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

BNBX2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
34.3%10/10

Revenue surging 34.3% year-over-year

Areas to Watch

BLK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Free Cash FlowQuality
$-1.19B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.142/10

Distress zone — elevated risk

BNBX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.72M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BLK

The strongest argument for BLK centers on Operating Margin, Revenue Growth, Market Cap. Profitability is solid with margins at 24.1% and operating margin at 35.1%. Revenue growth of 30.6% demonstrates continued momentum.

Bull Case : BNBX

The strongest argument for BNBX centers on Price/Book, Revenue Growth. Revenue growth of 34.3% demonstrates continued momentum. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bear Case : BLK

The primary concerns for BLK are Piotroski F-Score, Free Cash Flow, Altman Z-Score.

Bear Case : BNBX

The primary concerns for BNBX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

BLK profiles as a growth stock while BNBX is a hypergrowth play — different risk/reward profiles.

BLK carries more volatility with a beta of 1.44 — expect wider price swings.

BNBX is growing revenue faster at 34.3% — sustainability is the question.

BNBX generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

BLK scores higher overall (76/100 vs 48/100), backed by strong 24.1% margins and 30.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BlackRock Inc

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock, Inc. is an American multinational investment management corporation based in New York City.

Applied DNA Sciences, Inc.

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. The company is headquartered in Stony Brook, New York.

Want to dig deeper into these stocks?